Recursion Pharmaceuticals Inc - Ordinary Shares - Class A
RXRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.01B
Close$
Share Statistics
| Market cap | $2.01 Billion |
|---|---|
| Enterprise Value | $1.55 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.44 |
| Beta | 1.07 |
| Outstanding Shares | 532,460,085 |
Return
| Return on Equity | -56.71% |
|---|---|
| Return on Assets | -42.79% |
| Return on Invested Capital | -51.17% |
Valuation & Multiples
| P/E Ratio | -3.68 |
|---|---|
| PEG | 15.48 |
| Price to Sales | - |
| Price to Book Ratio | 3.7 |
| Enterprise Value to Revenue | 28.32 |
| Enterprise Value to EBIT | -2.78 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$10.97 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$12.98 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5325▼ 10.90% |
|---|---|
| Total Calls | 6,041,598▲ 31.47% |
| Total Puts | 3,217,300▲ 9.13% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 68.75%▲ 5.24% |
|---|---|
| Total Invested | $1.34B▲ 30.13% |
| Investors Holding | 361▲ 10.00% |
ESG Score
No data
About Recursion Pharmaceuticals Inc
218 employeesRecursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patient...